The Market

Cancer is one of the leading causes of death worldwide, with 14 million new cases diagnosed and 8 million related deaths each year. Overall, one in seven deaths worldwide are due to cancer.

The American Cancer Society estimates there will be more than 1.6 million new cancer cases diagnosed in the United States alone in 2015; more than 1,500 people a day are expected to die from the disease. The US National Institutes of Health (NIH) estimates that in the year 2020 the direct medical costs (total of all health expenditures) associated with cancer will be at least $158 billion–approximately 30% higher than the cost of cancer today.

To date, REOLYSIN® has shown activity in a broad range of cancers. Oncolytics is currently conducting clinical trials in six of the ten most common cancers diagnosed in men and five of the ten most diagnosed in women.

REOLYSIN® Addressable Market


1,000,000+ new U.S. cases a year in studied indications, of which REOLYSIN® conservatively addresses 60%

Source:AmericanCancerSociety– CancerFactsand Figures 2015 Estimated New Cases per Indication in the U.S. in 2015